According to the information furnished by the World Health Organization (WHO), it is estimated that cardiovascular diseases are the number 1 cause of death globally, in which three-quarters of the victims are residing in the low and middle-income countries. Amlodipine besylate belongs to the class of calcium channel blockers in due to its strong affinity for cell membranes modulating the calcium influx by inhibiting selected calcium channel membranes. These pharmacodynamic effects allows it to have a long-lasting effect and low dosing frequency.
Hypertension is reigning the clinical application segment for the amlodipine besylate market. As per the latest research citings presented by the World Health Organization (WHO), approximately 1 in 4 men and 1 in 5 women are suffering from hypertension across the globe. Chronic stable angina will be showcasing rampant market growth during the forecast period on account of the growing incidence of coronary artery disease worldwide. According to the research information provided by the Lancet Journal, it is estimated that 18% of the individuals suffering from coronary artery disease further suffer with angina attacks.
Browse the full report Amlodipine Besylate Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/amlodipine-besylate-market
Hospital pharmacy is representing the largest market share in the distribution channel segment for the amlodipine besylate market. It is imperative for the precise dispensing of amlodipine besylate under the medical supervision of hospital pharmacists to prevent the occurrence of side effects such as dizziness, drowsiness, swelling, etc. Retail pharmacy is expected to garner magnificent market performance in the near future owing to the flourishing generic drugs market and capacity to cater to the medicinal requirements of households residing in the remote locations.
North America is spearheading the geography segment for the amlodipine besylate market. The growing incidence of hypertension primarily drives market growth in the region. According to the latest research citings provided by the Center for Disease Control and Prevention (CDC) it is estimated that nearly half of the adult population in the United States is suffering from hypertension. Furthermore, the existence of key players such as Angita Pharma, Inc., Macleods Pharmaceuticals Limited, Apotex Corporation, etc., further propel market growth. Europe is placed 2nd in the regional segment on account of the growing incidence of angina pectoris in patients previously suffering from coronary artery disease. Additionally, the nurturing regulatory environment provided by the European Medical Agency (EMA), regarding the sale and distribution of amlodipine besylate drug formulations further accentuates the market growth. The Asia Pacific is anticipated to be the fastest-growing regional segment for the amlodipine besylate market on account of the flourishing generic drugs market and effective implementation of the treatment guidelines pertaining to the management of hypertension.
Pharmaceutical manufacturers actively engaged in the production of amlodipine besylate are Angita Pharma, Inc., Macleods Pharmaceuticals Limited., Merck KGaA., Cadila Healthcare., Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Apotex Corporation, Mylan Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited and Sandoz, Inc.
Key Market Movements:
- Rising prevalence of hypertension worldwide
- Growing incidence of angina pectoris in patients suffering from coronary artery disease across the globe
- Effective implementation of treatment guidelines pertaining to the management of cardiac complications further accentuates the market growth